Table of contents
Bone marrow - neoplastic myeloid
Recurrent genetic abnormalities:AML with BCR-ABL1 (pending)
AML with biallelic mutation of CEBPA
AML with mutated NPM1
AML with mutated RUNX1
AML with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
AML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBFB-MYH11
AML (megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1
AML with t(6;9)(p23;q34); DEK-NUP214
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
AML with t(9;11)(p22;q23); KMT2A-MLLT3
APL with PML-RARA
AML not otherwise specified:AML with minimal differentiation (FAB AML M0)
AML without maturation (FAB AML M1)
AML with maturation (FAB AML M2)
AMML (FAB AML M4)
AML M5
M5a
M5b
AML M6
AMKL M7
acute basophilic leukemia
AML with pseudo-Chediak-Higashi anomaly
AML hypocellular
Other AML entities defined by the WHO:acute panmyelosis with myelofibrosis
AML with myelodysplasia related changes
myeloid leukemia associated with Down syndrome
myeloid sarcoma
therapy related myeloid neoplasm (therapy related AML)
transient abnormal myelopoiesis associated with Down syndrome
Other AML of clinical relevance:AML with FLT3
Myelodysplastic syndromes (MDS):WHO classification - MDS
isolated del(5q)
MDS prognostic scoring (pending)
MDS in childhood
MDS with single lineage dysplasia
MDS with ring sideroblasts
MDS with multilineage dysplasia
MDS with excess blasts
MDS unclassifiable
refractory cytopenia of childhood (pending)
Myeloproliferative neoplasms (MPN):WHO classification - MPN
chronic eosinophilic leukemia
chronic myeloid leukemia (CML), BCR-ABL1 positive
chronic neutrophilic leukemia
essential thrombocythemia
MPN unclassifiable
polycythemia vera
primary myelofibrosis
MDS / MPN: WHO classification - MDS / MPN
atypical chronic myeloid leukemia; BCR-ABL1 negative
chronic myelomonocytic leukemia
juvenile myelomonocytic leukemia
MDS / MPN - unclassifiable
MDS / MPN with ring sideroblasts and thrombocytosis
Myeloid / lymphoid neoplasms with eosinophilia and gene rearrangement: PDGFRA rearrangement
PDGFRB rearrangement
FGFR1 rearrangement
PCM1-JAK2
Myeloid neoplasms with germline predisposition without a pre-existing disorder or organ dysfunction:AML with germline CEBPA mutation (pending)
with DDX41 mutation (pending)
Myeloid neoplasms with germline predisposition and pre-existing platelet disorders: with RUNX1 mutation (pending)
with ANKRD26 mutation (pending)
with ETV6 mutation (pending)
Myeloid neoplasms with germline predisposition and other organ dysfunction: with bone marrow failure (pending)
with GATA2 mutation
with telomere biology disorders (pending)
with Down syndrome (pending)
Bone marrow - plasma cell and lymphoid neoplasms
Plasma cell neoplasms:heavy chain disease
MGUS-IgM
MGUS-non IgM
non secretory myeloma (pending)
plasma cell leukemia (pending)
plasma cell myeloma (multiple myeloma)
plasmacytoma
POEMS syndrome (osteosclerotic myeloma)
TEMPI syndrome (pending)
Other:acute lymphoblastic leukemia / lymphoma
cryoglobulinemia
monoclonal immunoglobulin deposition diseases (pending)
primary amyloidosis
B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities:t(1;19)(q23;p13.3); TCF3-PBX1
t(5;14)(q31;q32); IGH / IL3
t(9;22)(q34;q11); BCR-ABL1
t(12;21)(p13;q22); ETV6-RUNX1
t(v;11q23); KMT2A rearranged
BCR-ABL1-like
therapy related B ALL
with hyperdiploidy
with hypodiploidy
with iAMP21 (pending)
NK and T cell precursor lymphoid neoplasms:early T cell precursor lymphoblastic leukemia (pending)
NK lymphoblastic leukemia/lymphoma (pending)
T lymphoblastic lymphoma / leukemia
Acute leukemia of ambiguous lineage: acute undifferentiated leukemia (pending)
ambiguous lineage NOS
mixed phenotype
Disorders from other chapters:
B lymphoblastic leukemia / lymphoma
crystal storing histiocytosis
cutaneous mastocytosis
heavy chain deposition disease
light chain deposition disease
Bone marrow neoplastic stains:
Lymphoblastic initial panel: CD1a CD3 CD4 CD5 CD7 CD8 CD10 CD20 CD34 PAX5 TdT
Refining panel: CD19 CD56 CD79a CD99 CD117 CD123 cleaved Notch1 myeloid markers
Primary marrow disorder initial screening: CD34 CD61 CD71 CD117 myeloperoxidase
Refining panel: CD11c CD42b E-cadherin glycophorin iron mast cell tryptase reticulin
Myeloma initial screening: CD138 kappa lambda
Refining panel: CD3 CD19 CD20 CD56 CD117 cyclin D1 EBER Ki67
FISH: myeloma prognostic probe sets
Bone marrow neoplastic stains:
Lymphoblastic initial panel: CD1a CD3 CD4 CD5 CD7 CD8 CD10 CD20 CD34 PAX5 TdT
Refining panel: CD19 CD56 CD79a CD99 CD117 CD123 cleaved Notch1 myeloid markers
Primary marrow disorder initial screening: CD34 CD61 CD71 CD117 myeloperoxidase
Refining panel: CD11c CD42b E-cadherin glycophorin iron mast cell tryptase reticulin
Myeloma initial screening: CD138 kappa lambda
Refining panel: CD3 CD19 CD20 CD56 CD117 cyclin D1 EBER Ki67
FISH: myeloma prognostic probe sets
Index (Alphabetical table of contents)
A-E:acute basophilic leukemia
acute lymphoblastic leukemia / lymphoma
acute panmyelosis with myelofibrosis
acute undifferentiated leukemia (pending)
ambiguous lineage NOS
AMKL M7
AML (megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1
AML hypocellular
AML M5
AML M6
AML with BCR-ABL1 (pending)
AML with biallelic mutation of CEBPA
AML with FLT3
AML with germline CEBPA mutation (pending)
AML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBFB-MYH11
AML with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
AML with maturation (FAB AML M2)
AML with minimal differentiation (FAB AML M0)
AML with mutated NPM1
AML with mutated RUNX1
AML with myelodysplasia related changes
AML with pseudo-Chediak-Higashi anomaly
AML with t(6;9)(p23;q34); DEK-NUP214
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
AML with t(9;11)(p22;q23); KMT2A-MLLT3
AML without maturation (FAB AML M1)
AMML (FAB AML M4)
APL with PML-RARA
atypical chronic myeloid leukemia; BCR-ABL1 negative
BCR-ABL1-like
blastic plasmacytoid dendritic cell neoplasm
chronic eosinophilic leukemia
chronic myeloid leukemia (CML), BCR-ABL1 positive
chronic myelomonocytic leukemia
chronic neutrophilic leukemia
cryoglobulinemia
cutaneous mastocytosis
early T cell precursor lymphoblastic leukemia (pending)
essential thrombocythemia
F-N:FGFR1 rearrangement
heavy chain disease
idiopathic hypereosinophilic syndrome
isolated del(5q)
juvenile myelomonocytic leukemia
M5a
M5b
mast cell sarcoma (pending)
MDS / MPN - unclassifiable
MDS / MPN with ring sideroblasts and thrombocytosis
MDS in childhood
MDS prognostic scoring (pending)
MDS unclassifiable
MDS with excess blasts
MDS with multilineage dysplasia
MDS with ring sideroblasts
MDS with single lineage dysplasia
MGUS-IgM
MGUS-non IgM
mixed phenotype
monoclonal immunoglobulin deposition diseases (pending)
MPN unclassifiable
myeloid leukemia associated with Down syndrome
myeloid sarcoma
NK lymphoblastic leukemia/lymphoma (pending)
non secretory myeloma (pending)
O-Z:PCM1-JAK2
PDGFRA rearrangement
PDGFRB rearrangement
plasma cell leukemia (pending)
plasma cell myeloma (multiple myeloma)
plasmacytoma
POEMS syndrome (osteosclerotic myeloma)
polycythemia vera
primary amyloidosis
primary myelofibrosis
refractory cytopenia of childhood (pending)
systemic mastocytosis
T lymphoblastic lymphoma / leukemia
t(12;21)(p13;q22); ETV6-RUNX1
t(1;19)(q23;p13.3); TCF3-PBX1
t(5;14)(q31;q32); IGH / IL3
t(9;22)(q34;q11); BCR-ABL1
t(v;11q23); KMT2A rearranged
TEMPI syndrome (pending)
therapy related B ALL
therapy related myeloid neoplasm (therapy related AML)
transient abnormal myelopoiesis associated with Down syndrome
VEXAS (pending)
WHO classification - AML
WHO classification - MDS
WHO classification - MDS / MPN
WHO classification - MPN
with ANKRD26 mutation (pending)
with DDX41 mutation (pending)
with ETV6 mutation (pending)
with RUNX1 mutation (pending)
with bone marrow failure (pending)
with Down syndrome (pending)
with GATA2 mutation
with hyperdiploidy
with hypodiploidy
with iAMP21 (pending)
with telomere biology disorders (pending)
Bone marrow neoplastic books
Cherry: 2021
Hsi: 2017
Hudnall: 2019
IARC: 2017
Jaffe: 2016
Kantarjian: 2016
Lanzkowsky: 2016
Naeim: 2018
Find related Pathology books: hematopathology, oncology, pediatric
